Kurzfassung

A 36 Week, Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Evalute the Efficency and Safety of Aliskiren on the Prevention of Left Ventricular Remodeling in High-risk Post-acute Myocardial Infarction Patients When Added to Optimized Standartd Therapy